Skip to content

Differential effects of ibogaine on local cerebral glucose utilization in drug-naive and morphine-dependent rats.

Beth Levant, Thomas L Pazdernik

Brain research April 2, 2004 DOI: 10.1016/j.brainres.2003.12.032 via PubMed

Summary

AI-generated from the abstract

Ibogaine, a hallucinogenic alkaloid proposed for treating opioid addiction, alters brain energy use differently in drug-naive versus morphine-dependent rats. In drug-naive rats, ibogaine increased glucose utilization in the parietal, cingulate, and occipital cortices and cerebellum, consistent with its hallucinogenic and tremor-inducing effects. In morphine-dependent rats, ibogaine caused a global decrease in brain glucose utilization, most notably in regions including the preoptic areas, nucleus accumbens shell, locus coeruleus, and flocculus. These distinct patterns suggest that ibogaine's hallucinogenic and anti-addictive effects may involve different brain mechanisms.

Study at a glance

Characteristics Experimental study Peer reviewed
Population Adult male Sprague-Dawley rats, drug-naive or morphine-dependent
Intervention Ibogaine
Dose 40 mg/kg
Keywords Ibogaine plant-derived compound Therapeutic applications Reward and addiction Brain energy use Glucose utilization
Citations 17
Key finding Ibogaine produces opposite effects on local cerebral glucose utilization in drug-naive rats (increases) versus morphine-dependent rats (global decreases), suggesting separate mechanisms for its hallucinogenic and anti-addictive actions.

Abstract

Ibogaine, a hallucinogenic indole alkaloid, has been proposed as a treatment for addiction to opioids and other drugs of abuse. The mechanism for its putative anti-addictive effects is unknown. In this study, the effects of ibogaine on local cerebral glucose utilization (LCGU) were determined in freely moving, drug-naive, or morphine-dependent adult, male, Sprague-Dawley rats using the [(14)C]2-deoxyglucose (2-DG) method. Morphine-dependent rats were treated with increasing doses of morphine (5-25 mg/kg, s.c., b.i.d.) and then maintained at 25 mg/kg (b.i.d.) for 4-7 days. For the 2-DG procedure, rats were injected with saline or ibogaine (40 mg/kg, i.p.). 2-DG was administered 1 h after administration of ibogaine. The rate of LCGU was determined by quantitative autoradiography in 46 brain regions. In drug-naive animals, ibogaine produced significant increases in LCGU in the parietal, cingulate, and occipital cortices and cerebellum compared to controls consistent with its activity as a hallucinogen and a tremorogen. Morphine-dependent rats had only minor alterations in LCGU at the time assessed in this experiment. However, in morphine-dependent animals, ibogaine produced a global decrease in LCGU that was greatest in brain regions such as the lateral and medial preoptic areas, nucleus of the diagonal band, nucleus accumbens shell, inferior colliculus, locus coeruleus, and flocculus compared to morphine-dependent animals treated with saline. These findings indicate that ibogaine produces distinctly different effects on LCGU in drug-naive and morphine-dependent rats. This suggests that different mechanisms may underlie ibogaine's hallucinogenic and anti-addictive effects.

Comments

No comments yet.

Log in to comment